Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Hypothermic Total Liquid Ventilation Is Highly Protective Through Cerebral Hemodynamic Preservation and Sepsis-Like Mitigation After Asphyxial Cardiac Arrest.

Kohlhauer M, Lidouren F, Remy-Jouet I, Mongardon N, Adam C, Bruneval P, Hocini H, Levy Y, Blengio F, Carli P, Vivien B, Ricard JD, Micheau P, Walti H, Nadeau M, Robert R, Richard V, Mulder P, Maresca D, Demené C, Pernot M, Tanter M, Ghaleh B, Berdeaux A, Tissier R.

Crit Care Med. 2015 Oct;43(10):e420-30. doi: 10.1097/CCM.0000000000001160.

PMID:
26110489
2.

Use of Attribute Driven Incremental Discretization and Logic Learning Machine to build a prognostic classifier for neuroblastoma patients.

Cangelosi D, Muselli M, Parodi S, Blengio F, Becherini P, Versteeg R, Conte M, Varesio L.

BMC Bioinformatics. 2014;15 Suppl 5:S4. doi: 10.1186/1471-2105-15-S5-S4. Epub 2014 May 6.

3.

Identification of a novel mouse Dbl proto-oncogene splice variant: evidence that SEC14 domain is involved in GEF activity regulation.

Ognibene M, Vanni C, Blengio F, Segalerba D, Mancini P, De Marco P, Torrisi MR, Bosco MC, Varesio L, Eva A.

Gene. 2014 Mar 10;537(2):220-9. doi: 10.1016/j.gene.2013.12.064. Epub 2014 Jan 9.

PMID:
24412292
4.

Identification of CD300a as a new hypoxia-inducible gene and a regulator of CCL20 and VEGF production by human monocytes and macrophages.

Raggi F, Blengio F, Eva A, Pende D, Varesio L, Bosco MC.

Innate Immun. 2014 Oct;20(7):721-34. doi: 10.1177/1753425913507095. Epub 2013 Oct 16.

PMID:
24131792
5.

Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC.

Balsamo M, Manzini C, Pietra G, Raggi F, Blengio F, Mingari MC, Varesio L, Moretta L, Bosco MC, Vitale M.

Eur J Immunol. 2013 Oct;43(10):2756-64. doi: 10.1002/eji.201343448. Epub 2013 Aug 5.

6.

Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients.

Cangelosi D, Blengio F, Versteeg R, Eggert A, Garaventa A, Gambini C, Conte M, Eva A, Muselli M, Varesio L.

BMC Bioinformatics. 2013;14 Suppl 7:S12. doi: 10.1186/1471-2105-14-S7-S12. Epub 2013 Apr 22.

7.

Chronic hypoxia reprograms human immature dendritic cells by inducing a proinflammatory phenotype and TREM-1 expression.

Pierobon D, Bosco MC, Blengio F, Raggi F, Eva A, Filippi M, Musso T, Novelli F, Cappello P, Varesio L, Giovarelli M.

Eur J Immunol. 2013 Apr;43(4):949-66. doi: 10.1002/eji.201242709. Epub 2013 Mar 6.

8.

Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.

Cornero A, Acquaviva M, Fardin P, Versteeg R, Schramm A, Eva A, Bosco MC, Blengio F, Barzaghi S, Varesio L.

BMC Bioinformatics. 2012 Mar 28;13 Suppl 4:S13. doi: 10.1186/1471-2105-13-S4-S13.

9.

The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cells.

Blengio F, Raggi F, Pierobon D, Cappello P, Eva A, Giovarelli M, Varesio L, Bosco MC.

Immunobiology. 2013 Jan;218(1):76-89. doi: 10.1016/j.imbio.2012.02.002. Epub 2012 Feb 10.

PMID:
22465745
10.

A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment.

Ferretti E, Bertolotto M, Deaglio S, Tripodo C, Ribatti D, Audrito V, Blengio F, Matis S, Zupo S, Rossi D, Ottonello L, Gaidano G, Malavasi F, Pistoia V, Corcione A.

Leukemia. 2011 Aug;25(8):1268-77. doi: 10.1038/leu.2011.88. Epub 2011 May 6.

PMID:
21546901
11.

Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo.

Bosco MC, Pierobon D, Blengio F, Raggi F, Vanni C, Gattorno M, Eva A, Novelli F, Cappello P, Giovarelli M, Varesio L.

Blood. 2011 Mar 3;117(9):2625-39. doi: 10.1182/blood-2010-06-292136. Epub 2010 Dec 10.

12.

Reference profile correlation reveals estrogen-like trancriptional activity of Curcumin.

Bachmeier BE, Mirisola V, Romeo F, Generoso L, Esposito A, Dell'eva R, Blengio F, Killian PH, Albini A, Pfeffer U.

Cell Physiol Biochem. 2010;26(3):471-82. doi: 10.1159/000320570. Epub 2010 Aug 24.

13.

Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration.

Bosco MC, Puppo M, Blengio F, Fraone T, Cappello P, Giovarelli M, Varesio L.

Immunobiology. 2008;213(9-10):733-49. doi: 10.1016/j.imbio.2008.07.031. Epub 2008 Sep 21. Review.

PMID:
18926289
14.

5-Fluorouracil dose intensification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: a phase II study.

Merlano M, Benasso M, Numico GM, Danova M, Santelli A, Ameli F, Blengio F, Ricci I, Rosso M.

Am J Clin Oncol. 1998 Jun;21(3):313-6.

PMID:
9626807
15.

Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.

Merlano M, Benasso M, Corvò R, Rosso R, Vitale V, Blengio F, Numico G, Margarino G, Bonelli L, Santi L.

J Natl Cancer Inst. 1996 May 1;88(9):583-9.

PMID:
8609658
16.

Concomitant administration of two standard regimens of chemotherapy and radiotherapy in advanced squamous carcinoma of the head and neck: a feasibility study.

Benasso M, Corvò R, Numico G, Cavallari M, Blengio F, Sanguineti G, Rosso M, Merlano M.

Anticancer Res. 1995 Nov-Dec;15(6B):2651-4.

PMID:
8669841
17.

Intensified chemotherapy with granulocyte-monocyte colony stimulating factor protection in advanced, relapsed squamous cell carcinoma of the head and neck. A phase I study.

Merlano M, Benasso M, Cavallari M, Blengio F, Sguotti C, Rosso M, Rosso R.

Am J Clin Oncol. 1994 Dec;17(6):494-7.

PMID:
7977167
18.

Chemotherapy in head and neck cancer.

Merlano M, Benasso M, Cavallari M, Blengio F, Rosso M.

Eur J Cancer B Oral Oncol. 1994 Sep;30B(5):283-9. Review.

PMID:
7535608
19.

Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck.

Colella E, Merlano M, Blengio F, Angelini F, Ausili Cefaro GP, Scasso F, Lo Russo V, Cirulli S, Giannarelli D, Cognetti F.

Eur J Cancer. 1994;30A(7):928-30.

PMID:
7946585
20.

Concomitant alpha-interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck.

Benasso M, Merlano M, Blengio F, Cavallari M, Rosso R, Toma S.

Am J Clin Oncol. 1993 Dec;16(6):465-8.

PMID:
8256758

Supplemental Content

Loading ...
Support Center